Download PDF

1. Company Snapshot

1.a. Company Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.Iteos Therapeutics, Inc.


was founded in 2011 and is headquartered in Watertown, Massachusetts.

Show Full description

1.b. Last Insights on ITOS

iTeos Therapeutics' recent performance was driven by a strong cash position, with a balance of $624.3 million as of March 31, 2025, expected to provide runway through 2027. The company's pipeline advancements, including the completion of enrollment in the EOS-984 + pembrolizumab combination Phase 1 trial and the anticipated start of EOS-215 Phase 1 trial TRM-010 patient enrollment in 2Q25, contributed to the positive sentiment. Additionally, the company's presentation of preclinical data on EOS-215 and a novel PTPN1/2 inhibitor at the American Association for Cancer Research Annual Meeting 2025 showcased its innovative approach to immuno-oncology therapeutics.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of Shareholders

Aug -20

Source: prnewswire.com

Card image cap

ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS

Aug -20

Source: globenewswire.com

Card image cap

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders

Jul -22

Source: globenewswire.com

Card image cap

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.

Jul -21

Source: prnewswire.com

Card image cap

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Veritex Holdings, Inc. (NASDAQ: VBTX)

Jul -21

Source: globenewswire.com

Card image cap

ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders

Jul -21

Source: businesswire.com

Card image cap

iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

Jul -21

Source: globenewswire.com

Card image cap

iTeos Therapeutics Announces Its Intention to Wind Down Operations

May -28

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Cancer Immunotherapies

Expected Growth: 11.3%

iTeos Therapeutics, Inc.'s Cancer Immunotherapies segment growth of 11.3% is driven by increasing adoption of novel checkpoint inhibitors, rising incidence of cancer, and growing demand for targeted therapies. Additionally, advancements in biomarker development, expansion into new indications, and strategic partnerships are contributing to the segment's rapid growth.

7. Detailed Products

EOS-448

A potent and selective adenosine A2A receptor antagonist for the treatment of solid tumors

EOS-811

A potent and selective anti-TIGIT antibody for the treatment of solid tumors

EOS-610

A potent and selective A2B receptor antagonist for the treatment of solid tumors

EOS-942

A potent and selective anti-PD-1 antibody for the treatment of solid tumors

8. iTeos Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

iTeos Therapeutics, Inc. operates in a highly competitive industry with many substitutes available, but the company's focus on innovative cancer therapies and its strong research and development capabilities help to mitigate the threat of substitutes.

Bargaining Power Of Customers

iTeos Therapeutics, Inc. has a diverse customer base, and no single customer has significant bargaining power, reducing the company's dependence on individual customers.

Bargaining Power Of Suppliers

iTeos Therapeutics, Inc. relies on a few key suppliers for raw materials and services, but the company's strong relationships with suppliers and its ability to negotiate favorable terms help to mitigate the bargaining power of suppliers.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services, posing a significant threat to iTeos Therapeutics, Inc.'s market share.

Intensity Of Rivalry

The biotechnology industry is highly competitive, and iTeos Therapeutics, Inc. faces intense rivalry from established companies and new entrants, which can lead to pricing pressures and reduced market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 1.04%
Debt Cost 3.95%
Equity Weight 98.96%
Equity Cost 10.29%
WACC 10.22%
Leverage 1.05%

11. Quality Control: iTeos Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Puma Biotechnology

A-Score: 5.6/10

Value: 7.4

Growth: 6.1

Quality: 8.7

Yield: 0.0

Momentum: 9.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
CytomX Therapeutics

A-Score: 5.3/10

Value: 5.7

Growth: 6.2

Quality: 9.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Harmony Biosciences

A-Score: 5.2/10

Value: 7.0

Growth: 9.4

Quality: 9.0

Yield: 0.0

Momentum: 1.5

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
iTeos Therapeutics

A-Score: 4.6/10

Value: 7.8

Growth: 3.6

Quality: 6.2

Yield: 0.0

Momentum: 6.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Akebia Therapeutics

A-Score: 4.6/10

Value: 4.8

Growth: 5.8

Quality: 5.8

Yield: 0.0

Momentum: 10.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Amylyx Pharmaceuticals

A-Score: 4.3/10

Value: 8.2

Growth: 3.6

Quality: 7.2

Yield: 0.0

Momentum: 5.0

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

10.15$

Current Price

10.15$

Potential

-0.00%

Expected Cash-Flows